A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

This purpose of this study is to see if an investigational inhaled medication is safe and effective for the treatment of parainfluenza virus(PIV) in patients with weakened immune systems. Key eligibility criteria are being diagnosed with PIV having received a solid organ or stem cell transplant at any time in the past, or past history of being treated with chemotherapy for solid tumor or blood-related malignancy. The main study intervention is treatment with study drug or placebo for 7-10 days.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  PIV, cancer history
• Age: - 99 Years
• Gender: All